<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037478</url>
  </required_header>
  <id_info>
    <org_study_id>4SC-201-2-2009</org_study_id>
    <nct_id>NCT01037478</nct_id>
  </id_info>
  <brief_title>Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma</brief_title>
  <acronym>SAPHIRE</acronym>
  <official_title>A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients With Relapsed or Refractory Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>4SC AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>4SC AG</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Resminostat (4SC-201) is effective and safe
      in the treatment of relapsed or refractory Hodgkin's Lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the best overall objective response rate (ORR) based on IWG criteria of Resminostat (4SC-201) in patients with refractory or relapsed Hodgkin's Lymphoma.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigation of the safety and tolerability of repeated oral doses of Resminostat (4SC-201)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the overall survival (OS)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of progression free survival (PFS), including radiological and symptomatic progression</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of time to progression (TTP), including objective and symptomatic progression</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of duration of response (DOR)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the pharmacokinetics of Resminostat (4SC-201) after oral dosing</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Resminostat (4SC-201)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resminostat (4SC-201)</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Resminostat (4SC-201)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patients must have histological or cytological evidence of Hodgkin's Lymphoma (all
             subtypes are acceptable)

          -  Patients must have relapsed or refractory Hodgkin's Lymphoma (HL) defined as relapse
             following initial therapy or lack of response to first line therapy and treatment with
             second-line (salvage therapy). Patients may have also undergone high-dose chemotherapy
             with autologous stem cell transplantation at least 12 weeks prior to study entry

          -  Patients must have measurable anatomical disease present on CT scan

          -  Patients must have an ECOG Performance Score of 0, 1 or 2

        Main Exclusion Criteria:

          -  Patients who have received previous treatment with an HDAC inhibitor

          -  Patients who have undergone allogeneic hematopoietic stem cell transplantation

          -  Patients with known or suspected involvement of the CNS by HL

          -  Patients treated with agents known to prolong the QT interval or with a confirmed QTcF
             &gt; 450 msec

          -  Patients with a history of other malignancies unless having undergone definitive
             treatment more than 5 years prior to entry into the study and without evidence of
             recurrent malignant disease, excluding patients with basal cell carcinoma of the skin;
             superficial carcinoma of the bladder; carcinoma of the prostate with a current PSA &lt;
             0.1 ng/ml; or cervical intraepithelial neoplasia

          -  Patients with a history of significant cardiovascular, neurological, endocrine,
             gastrointestinal, respiratory or inflammatory illness that could preclude their
             participation in the trial, pose an undue medical hazard or interfere with the
             interpretation of the trial results, including, but not limited to, patients with
             congestive heart failure (NYHA Class 3 or 4); unstable angina; cardiac arrhythmia;
             recent (within the preceding 6 months) myocardial infarction or stroke; hypertension
             requiring &gt; 2 medications for adequate control; diabetes mellitus with &gt; 2 episodes of
             ketoacidosis in the preceding 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Walewski, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instytut im. Marii Skłodowskiej-Curie, Centrum Onkologii, Warsaw, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fakultní nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Hradec Kralové</name>
      <address>
        <city>Hradec Kralové</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr.1 w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut im. Marii Sklodowskiej-Curie, Centrum Onkologii</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr.1 we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Clinic Fundeni</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Coltea</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <last_update_submitted>January 15, 2014</last_update_submitted>
  <last_update_submitted_qc>January 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2014</last_update_posted>
  <keyword>Hodgkin's Lymphoma</keyword>
  <keyword>HDAC</keyword>
  <keyword>4SC-201</keyword>
  <keyword>Resminostat</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

